Fig. 4: ZIC2 facilitates exit from naïve pluripotency.
From: ZIC2 and ZIC3 promote SWI/SNF recruitment to safeguard progression towards human primed pluripotency
a Schematic of experiments designed to determine where 3xFlag-ZIC2 localises to on chromatin and how it affects naïve pluripotency. b Brightfield images of TetON-ZIC2 naïve hESCs upon treatment with doxycycline compared to DMSO control. Scale bar 100 μm. Data are representative of two biological replicates. c Contour plots showing expression of CD75 and CD24 in TetON-ZIC2 naïve hESCs upon treatment with doxycycline compared to DMSO control. d Volcano plot showing number of DEGs in naïve hESCs upon ectopic expression of ZIC2. P values were calculated from a two-tailed Wald test and adjusted for multiple comparisons by the Benjamini–Hochberg procedure. e 2D plot showing overlap of genes that become differentially expressed upon ectopic expression of ZIC2 in naïve hESCs, with genes that are differentially expressed in naïve and primed hESCs. TPM transcripts per million. f Experimental setup to test lineage potency of naïve hESCs in response to ASECRiAV medium, upon ectopic expression of ZIC2 or ZIC3. g (Top) Expression of ZIC2 in naïve hESCs upon treatment with doxycycline for different timepoints. (Bottom) Expression of AMLC markers in naïve hESCs pre-treated with doxycycline for different timepoints and then cultured in ASECRiAV medium. Gene expression trends are shown. Source data are provided as a Source Data file.
